Press Detail





News: Biotest AG: Biotest sold US therapy business to ADMA Biologics, Inc.

News: Biotest AG / Key word(s): Disposal
Biotest AG: Biotest sold US therapy business to ADMA Biologics, Inc.

07.06.2017 / 09:00
The issuer is solely responsible for the content of this announcement.



PRESS RELEASE


Biotest sold US therapy business to ADMA Biologics, Inc.

- Biotest receives 50% minus one share of ADMA

- Biotest receives also distribution rights of specified current product and
a right of first offer for the distribution of future products of ADMA for
Europe, Near and Middle East and selected Asian countries


Dreieich, 7 June 2017. Biotest's US subsidiary, Biotest Pharmaceuticals
Corporation, Boca Raton, Florida, USA, (BPC), has closed the agreement with
ADMA Biologics, Inc., Ramsey, New Jersey, USA, (ADMA) to sell certain assets
of the US therapy business after customary closing conditions, including
approval of ADMA's shareholders, were fulfilled.
Included in the assets to be transferred are BPC's plasma fractionation
facility, its commercial products, contract manufacturing agreements as well
as BPC's Boca Raton, Florida headquarters and real properties.

Biotest received equity interest in ADMA's issued and outstanding capital
stock in the form of 50% minus one share representing 25% of the voting
rights. In addition, Biotest will:

- Receive two ADMA plasma centers in the USA on January 1, 2019

- Obtain distribution rights for ADMA's innovative product (RI-002) and a
right of first offer for the distribution of future ADMA developed
plasma-based products in Europe, Near and Middle East and selected Asian
countries

- Participate from the future development of products in the USA

As part of the transaction, Biotest has contributed EUR11.5 million in cash
as well as a EUR14 million loan. The loan bears 6% interest and has a term
of 5 years. In addition, Biotest will contribute up to EUR11.5 million
towards a future capital increase of ADMA on equal terms as third party
investors.

"We are pleased that all closing conditions are fulfilled and that Biotest
is now a significant shareholder of ADMA." said Dr. Bernhard Ehmer, Chief
Executive Officer and Chairman of the Board of Management of Biotest AG.
"With the further development of the hyperimmune portfolio we have the
opportunity to maximize the market potential of the assets."

About ADMA Biologics, Inc.
ADMA is a biopharmaceutical company that develops, manufactures and intends
to commercialize specialty plasma-based biologics for the treatment and
prevention of Primary Immune Deficiency Disease (PIDD) and certain
infectious diseases. ADMA's mission is to develop and commercialize
plasma-derived, human immune globulins targeted to niche patient populations
for the treatment and prevention of certain infectious diseases. The target
patient populations include immune-compromised individuals who suffer from
an underlying immune deficiency disease, or who may be immune-compromised
for medical reasons. For more information, please visit the company's
website at www.admabiologics.com.

About RI-002
ADMA's lead product candidate, RI-002, is a specialty plasma-derived,
polyclonal, intravenous immune globulin (IGIV) derived from human plasma
containing naturally occurring polyclonal antibodies (e.g., Streptococcus
pneumoniae, H. influenza type B, cytomegalovirus (CMV), measles, tetanus,
etc.) as well as standardized, high levels of antibodies to respiratory
syncytial virus (RSV). ADMA is pursuing an indication for the use of this
specialty intravenous immune globulin (IGIV) product for treatment of
patients diagnosed with PIDD. Polyclonal antibodies are the primary active
component of IGIV products. Polyclonal antibodies are proteins that are used
by the body's immune system to neutralize microbes, such as bacteria and
viruses. Data review indicates that the polyclonal antibodies present in
RI-002 support its ability to prevent infections in immune-compromised
patients.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.




07.06.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de



Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange



End of News DGAP News Service


580929 07.06.2017